米・FDAが抗PD-1抗体Libtayo(cemiplimab-rwlc)について、転移性または局所進行性の皮膚扁平上皮がんを適応として承認【米・Regeneron】

 皮膚扁平上皮がんに対する治療薬を米・FDAが承認したのは今回初となる。

 The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation. This is the first FDA approval of a drug specifically for advanced CSCC.

 

コメント

Leave a comment

Your email address will not be published.


*